Sugi Predict

Sugi Predict / Compounds / SCHEMBL3622173

SCHEMBL3622173

SCHEMBL3622173

C#Cc1ccccc1CC(=O)NC(=S)Nc1ccc(Oc2ccnc3cc(-c4ccc(CNCCOC)cn4)sc23)c(F)c1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MET P08581 19/20 0.80
▸ KDR P35968 19/20 0.80
▸ AXL P30530 2/20 0.80
▸ FLT3 P36888 2/20 0.80
▸ MST1R Q04912 2/20 0.80
▸ PLK4 O00444 1/20 0.80
▸ MAP4K4 O95819 1/20 0.80
▸ ABL1 P00519 1/20 0.80
▸ LCK P06239 1/20 0.80
▸ FYN P06241 1/20 0.80
▸ LYN P07948 1/20 0.80
▸ HCK P08631 1/20 0.80
▸ PDGFRB P09619 1/20 0.80
▸ BCR P11274 1/20 0.80
▸ SRC P12931 1/20 0.80
▸ ABL2 P42684 1/20 0.80
▸ FRK P42685 1/20 0.80
▸ SYK P43405 1/20 0.80
▸ DDR1 Q08345 1/20 0.80
▸ MERTK Q12866 1/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13926615 0.92 MET (0.85) METKDRAXLFLT3MST1R
SCHEMBL2670905 0.92 MET (0.86) METKDRAXLFLT3MST1R
SCHEMBL2673548 0.91 MET (0.91) METKDRAXLFLT3MST1R
Glesatinib SCHEMBL106319 0.89 MET (1.00) METKDRAXLFLT3MST1R
Glesatinib SCHEMBL29351360 0.89 MET (1.00) METKDRAXLFLT3MST1R
SCHEMBL13167449 0.88 MET (0.91) METKDRAXLFLT3MST1R
SCHEMBL3658573 0.86 MET (0.78) METKDRAXLFLT3MST1R
SCHEMBL2670920 0.85 MET (0.72) METKDRAXLFLT3MST1R
SCHEMBL2670766 0.84 MET (0.77) METKDRAXLFLT3MST1R
SCHEMBL2670912 0.83 MET (0.72) METKDRAXLFLT3MST1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060287343-A1 INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING METHYLGENE, INC. 2006-12-21 — — US claimed
US-20100249145-A1 Inhibitors of VEGF Receptor and HGF Receptor Signaling METHYLGENE, INC. 2010-09-30 — — US disclosed
US-20100249145-A1 Inhibitors of VEGF Receptor and HGF Receptor Signaling METHYLGENE, INC. 2010-09-30 — — US disclosed
US-20100249145-A1 Inhibitors of VEGF Receptor and HGF Receptor Signaling METHYLGENE, INC. 2010-09-30 — — US disclosed
US-7790729-B2 Inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE INC. (CA) 2010-09-07 — — US disclosed
US-7790729-B2 Inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE INC. (CA) 2010-09-07 — — US disclosed
US-7790729-B2 Inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE INC. (CA) 2010-09-07 — — US disclosed
US-20060287343-A1 INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING METHYLGENE, INC. 2006-12-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060287343-A1 INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING HGF, MET, FLT1 MET 2/4885KDR 4/4885AXL 370/4885
US-20100249145-A1 Inhibitors of VEGF Receptor and HGF Receptor Signaling HGF, MET, FLT1 MET 2/4885KDR 4/4885AXL 370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.